title: Effect of recombinant human granulocyte colony stimulating factor on granulocytopenia induced by cytotoxic chemotherapy in patients with multiple myeloma.
abstract: 15 multiple myeloma patients with severe granulocytopenia after chemotherapy were treated with recombinant human granulocyte colony stimulating factor (Neupogen; Roche). Granulocyte colony stimulating factor (G-CSF) was given s.c. usually in a dose of 5 micrograms/kg for 5-14 (median:8) days. In all cases the increase in ANC was observed; one day after completing therapy the ANC ranged from 2.3 to 19.7 (mean: 10.3) x 10(9)/l. In 3 cases the ANC peak appeared during first (2-4) days of treatment, in one- on 14-th day after 10-day unsuccesful treatment. Generally, ANCs rapidly decreased after discontinuation of treatment to the values observed prior to the last chemotherapy. Both adverse events present in 9 patients and changes in monitored blood biochemistry components were moderate and reversible. In 3 cases symptoms of myeloma progression occurred. The study showed that G-CSF is an efficient and well tolerated drug, but also demonstrated its short-term action.
authors.affiliation: Department of Hematology, Institute of Hematology and Blood Transfusion, Warszawa, Poland.
authors.forename: R
authors.initials: R
authors.lastname: Pogłód
authors.forename: M
authors.initials: M
authors.lastname: Kraj
authors.forename: S
authors.initials: S
authors.lastname: Maj
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000380:Agranulocytosis / Q000139:chemically induced* / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000188:drug therapy; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor